Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
H Clinical is the leader in decentralized clinical trial support and home visits in Latin America
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
The total covered market size of four brands – Z&D, Pediclory, Pecef & Ezinapi combined is Rs 1800 crores
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
The settlement and dismissal resolves all claims between the parties
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
Doctors will study for a Master of Surgery or Master of Medicine degree at Edge Hill University.
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
HIL has set up the Bti bio-larvicide manufacturing facility at its Rasayani Plant at Maharashtra with the financial assistance of GEF/UNIDO under the project
The Congress was held on June, 20-21, 2022 in Berlin, Germany
Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million.
Aurobindo Pharma Foundation endeavours to make a positive contribution to the underprivileged ommunities by supporting a wide range of socio-economic, educational, and health initiatives.
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
Silo enters into commercial evaluation license agreement for next generation liposomes
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)
